Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels

Background null Immune checkpoint inhibitors have improved the management of metastatic melanoma, however, we have witnessed an emergence of adverse cardiac events such as myocarditis. null Objectives null We first aimed to assess the prevalence of adverse cardiac events in patients treated with anti-PD-1 for metastatic melanoma. Our second objective was to determine the role of troponin monitoring in the diagnosis of these events. null...